Efficacy and Safety of Agomelatine (25 Mg/Day With Potential Adjustment to 50 Mg) Given Orally for Eight Weeks in Out-Patients With Severe Major Depressive Disorder: A Randomised Double-Blind, Parallel Groups, International Study Versus Selective Serotonin Reuptake Inhibitor (SSRI) With a Double-Blind Extension Period of 16 Weeks

doi 10.1186/isrctn19313268